Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Short Interest Update

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) was the target of a large growth in short interest in the month of September. As of September 15th, there was short interest totaling 1,297,436 shares, a growth of 3,691.1% from the August 31st total of 34,223 shares. Currently, 0.1% of the shares of the company are short sold. Based on an average daily trading volume, of 588,083 shares, the short-interest ratio is presently 2.2 days.

Shionogi & Co., Ltd. Unsponsored ADR Stock Performance

Shionogi & Co., Ltd. Unsponsored ADR stock traded down $0.14 during midday trading on Thursday, hitting $9.20. The company’s stock had a trading volume of 74,200 shares, compared to its average volume of 141,757. Shionogi & Co., Ltd. Unsponsored ADR has a 1-year low of $7.65 and a 1-year high of $12.00. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.14 and a quick ratio of 1.00. The company has a 50-day moving average price of $9.07 and a two-hundred day moving average price of $9.47. The company has a market cap of $15.66 billion, a price-to-earnings ratio of 9.20, a PEG ratio of 3.37 and a beta of 0.08.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) last announced its earnings results on Monday, August 3rd. The company reported $0.36 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.18 by $0.18. Shionogi & Co., Ltd. Unsponsored ADR had a net margin of 46.67% and a return on equity of 16.13%. The firm had revenue of $1.04 billion for the quarter, compared to analyst estimates of $970.69 million. As a group, sell-side analysts predict that Shionogi & Co., Ltd. Unsponsored ADR will post 0.82 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts have issued reports on the stock. Jefferies Financial Group upgraded shares of Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, July 14th. The Goldman Sachs Group raised Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong-buy” rating in a research report on Monday, June 15th. Two research analysts have rated the stock with a Strong Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, Shionogi & Co., Ltd. Unsponsored ADR has a consensus rating of “Buy”.

Shionogi & Co., Ltd. Unsponsored ADR Company Profile

Shionogi & Co, Ltd. is a Japan-based pharmaceutical company that researches, develops, manufactures and markets prescription medicines. Founded in Osaka in 1878, the company has built its business around drug discovery and has a particular focus on infectious diseases, including antiviral and antibacterial treatments.

Shionogi’s products include Xofluza (baloxavir marboxil), an oral treatment for influenza, and Fetcroja (cefiderocol), an antibiotic used for certain difficult-to-treat bacterial infections.